Glaukos Corp (GKOS) Peer Comparison

$158.56

$4.13 (2.67%)

As on 28-Sep-2026 16:00EDT

Market cap

$9,521 Mln

Revenue (TTM)

$613 Mln

P/E Ratio

--

P/B Ratio

14.1

Div. Yield

0 %

Edit

	Glaukos Corp (GKOS)	Penumbra (PEN)	Avantor (AVTR)	Bio-Rad Laboratories	Repligen (RGEN)
Market cap ($ Mln)	9,521	12,560	10,497	9,770	10,705
Revenue ($ Mln)	613	1,505	6,561	2,589	785
Net Profit ($ Mln)	-188.05	160.59	-578.00	222.40	41.54
Net Margin (%)	-30.68	10.67	-8.81	8.59	5.29
RoE (%)	-28.10	10.86	-10.33	3.04	1.97
Price to Earnings	--	78.15	--	44.47	263.44
Price-To-Book	14.13	8.19	1.91	1.36	4.93

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Glaukos Corp (GKOS)	Penumbra (PEN)	Avantor (AVTR)	Bio-Rad Laboratories	Repligen (RGEN)
Operating Revenue	612.84	1,504.87	6,561.10	2,589.30	785.10
Cost of Revenue	127.96	483.98	4,473.00	1,245.50	384.30
Gross Profit	393.22	942.44	2,139.40	1,343.60	347.62
Operating Expenses	565.37	833.56	2,373.70	1,108.90	335.50
Operating Profit (EBIT)	-80.49	187.34	-285.60	235.00	65.30
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-192.83	203.83	-472.00	350.40	52.15
Provision for Tax	-4.79	43.24	106.00	128.00	10.61
Profit after Tax (Net Income)	-188.05	160.59	-578.00	222.40	41.54
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Glaukos Corp (GKOS)	Penumbra (PEN)	Avantor (AVTR)	Bio-Rad Laboratories	Repligen (RGEN)
Shareholder's Funds	682.49	1,530.77	5,630.20	7,173.90	2,112.03
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	135.71	210.18	4,583.70	2,116.80	705.49
Current Liabilities	102.33	233.78	1,382.00	961.30	132.66
Total Liabilities	893.49	1,826.52	11,794.70	10,576.50	2,949.70

Assets ($ Mln)

	Glaukos Corp (GKOS)	Penumbra (PEN)	Avantor (AVTR)	Bio-Rad Laboratories	Repligen (RGEN)
Non-Current Assets	404.74	630.60	9,133.70	7,231.50	1,749.63
Current Assets	515.78	1,344.12	2,462.20	3,020.50	1,200.55
Total Assets	893.49	1,826.52	11,794.70	10,576.50	2,949.70
Total Debt*	102.84	212.71	3,697.80	1,203.70	690.94
Net Current Assets	413.45	1,110.35	1,080.20	2,059.20	1,067.90

Cashflow ($ Mln)

	Glaukos Corp (GKOS)	Penumbra (PEN)	Avantor (AVTR)	Bio-Rad Laboratories	Repligen (RGEN)
Cash From Operating Activities	-46.34	238.66	623.80	532.20	117.42
Cash Flow from Investing Activities	-77.61	-404.59	-130.50	-189.70	-298.47
Cash from Financing Activities	11.89	26.53	-409.40	-283.20	-15.21
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Glaukos Corp (GKOS)	Penumbra (PEN)	Avantor (AVTR)	Bio-Rad Laboratories	Repligen (RGEN)
ROCE (%)	-22.53	11.76	-5.43	8.98	1.79
ROE (%)	-28.10	10.86	-10.33	3.04	1.97
ROA (%)	-18.00	7.95	-4.08	2.02	1.36
EBIT Margin (%)	-30.58	13.63	-4.47	-5.99	9.87
Net Margin (%)	-30.68	10.67	-8.81	8.59	5.29
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Glaukos Corp (GKOS)	Penumbra (PEN)	Avantor (AVTR)	Bio-Rad Laboratories	Repligen (RGEN)
Revenue Growth (%)	41.55	17.55	-1.57	1.37	16.49
EBIT Growth (%)	-116.42	17.49	-129.16	-131.06	920.91
Net Profit Growth (%)	-102.66	8.72	-184.08	-30.32	400.42
EPS Growth (%)	-96.88	8.12	-184.11	-29.66	394.30
Book Value Growth (%)	-12.65	17.33	-9.82	2.19	2.16

Valuation Ratios

	Glaukos Corp (GKOS)	Penumbra (PEN)	Avantor (AVTR)	Bio-Rad Laboratories	Repligen (RGEN)
Price / Earnings	-34.59	68.93	-14.68	--	189.42
Price / Book Value	9.90	8.58	1.40	--	4.40
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-43.50	53.25	81.94	--	55.90
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Glaukos Corp (GKOS)	Penumbra (PEN)	Avantor (AVTR)	Bio-Rad Laboratories	Repligen (RGEN)
Debt to Equity	0.00	0.00	0.65	0.11	0.26
Short term debt to equity ratio	0.00	0.01	0.01	0.06	0.01
Current Ratio	5.04	5.75	1.78	3.14	9.05
Quick Ratio	4.46	3.86	1.18	2.33	7.64
Interest Coverage	-38.31	157.91	-1.64	8.18	1.92

Operating Efficiency Ratios

	Glaukos Corp (GKOS)	Penumbra (PEN)	Avantor (AVTR)	Bio-Rad Laboratories	Repligen (RGEN)
Debtors to sales (%)	22.67	12.65	17.36	17.06	20.09
Asset Turnover	0.59	0.74	0.46	0.24	0.26
Receivable days	60.95	46.54	58.79	65.39	72.41
Inventory Days	193.84	331.92	64.13	221.09	146.53
Payable days	60.19	26.16	58.13	37.02	29.05
Cash Conversion Cycle	194.60	352.30	64.79	249.46	189.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly